Evidence map›Paper›PMID 24366465›Full record

SynthesisPediatric research2013

Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.

Vinod K Bhutani, Alvin Zipursky, Hannah Blencowe, Rajesh Khanna, Michael Sgro, Finn Ebbesen, Jennifer Bell, Rintaro Mori, Tina M Slusher, Nahed Fahmy and 8 more

Open access · hybridAbstract readHistorical ArticleMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pediatric research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed, 8 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

179 citing papers in PubMed, 8 syntheses or guidelines pooled it, 488 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. FIGO/ICM guidelines for preventing Rhesus disease: A call to action.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2021
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia.Journal of perinatology : official journal of the California Perinatal Association · 2016
    Trial
  15. Review
  16. Article
  17. Universal newborn screening for G6PD deficiency and severe hyperbilirubinemia at a tertiary center in Jerusalem.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  18. Article
  19. Article
  20. Article

119 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 10 countries.

Vinod K Bhutani1] Programme for Global Paediatric Research (PGPR), Hospital for Sick Children, Toronto, Ontario, Canada [2] Division of Neonatal and Developmental Medicine, Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, California.
Alvin ZipurskyProgramme for Global Paediatric Research (PGPR), Hospital for Sick Children, Toronto, Ontario, Canada.
Hannah BlencoweFaculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Rajesh KhannaSaving Newborn Lives/Save the Children, New Delhi, India.
Michael SgroKeenan Research Centre, Li Ka Shing Knowledge Institute & Department of Paediatrics, St. Michael's Hospital, Toronto, Ontario, Canada.
Finn EbbesenDepartment of Pediatrics, Aalborg University Hospital, Aalborg, Denmark.
Jennifer BellProgramme for Global Paediatric Research (PGPR), Hospital for Sick Children, Toronto, Ontario, Canada.
Rintaro MoriDepartment of Health Policy, National Center for Child Health and Development, Tokyo, Japan.
Tina M Slusher1] Programme for Global Paediatric Research (PGPR), Hospital for Sick Children, Toronto, Ontario, Canada [2] Center for Global Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Nahed FahmyDepartment of Pediatrics, Kasr Al Aini University, El Mounira Children's Hospital, Cairo, Egypt.
Vinod K PaulWHO Collaborating Centre for Training & Research in Newborn Care, All India Institute of Medical Sciences, New Delhi, India.
Lizhong DuThe Children's Hospital, Zhejiang University School of Medicine, Hangzhou, The People's Republic of China.
Angela A OkoloNigerian Society of Neonatal Medicine, Lagos, Nigeria.
Maria-Fernanda de AlmeidaFederal University of São Paulo-UNIFESP, São Paulo, Brazil.
Bolajoko O OlusanyaCenter for Healthy Start Initiative, Lagos, Nigeria.
Praveen KumarPost Graduate Institute of Medical Education and Research, Chandigarh, India.
Simon CousensSaving Newborn Lives/Save the Children, New Delhi, India.
Joy E Lawn1] Centre for Maternal Reproductive & Child Health, London School of Hygiene & Tropical Medicine, London, UK [2] Saving Newborn Lives/Save the Children, Washington, DC.
Hospital for Sick Children · CALondon School of Hygiene & Tropical Medicine · GBAalborg University Hospital · DKAll India Institute of Medical Sciences · INCentre for Healthy Start Initiative · NGChildren Cancer Hospital · EGChildren's Hospital of Zhejiang University · CNNational Center For Child Health and Development · JPPost Graduate Institute of Medical Education and Research · INSociety of Gynaecology and Obstetrics of Nigeria · NGSt. Michael's Hospital · CAUniversidade Federal de São Paulo · BRUniversity of Minnesota Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRhesus (Rh) disease and extreme hyperbilirubinemia (EHB) result in neonatal mortality and long-term neurodevelopmental impairment, yet there are no estimates of their burden.

methodsSystematic reviews and meta-analyses were undertaken of national prevalence, mortality, and kernicterus due to Rh disease and EHB. We applied a compartmental model to estimate neonatal survivors and impairment cases for 2010.

resultsTwenty-four million (18% of 134 million live births ≥ 32 wk gestational age from 184 countries; uncertainty range: 23-26 million) were at risk for neonatal hyperbilirubinemia-related adverse outcomes. Of these, 480,700 (0.36%) had either Rh disease (373,300; uncertainty range: 271,800-477,500) or developed EHB from other causes (107,400; uncertainty range: 57,000-131,000), with a 24% risk for death (114,100; uncertainty range: 59,700-172,000), 13% for kernicterus (75,400), and 11% for stillbirths. Three-quarters of mortality occurred in sub-Saharan Africa and South Asia. Kernicterus with Rh disease ranged from 38, 28, 28, and 25/100,000 live births for Eastern Europe/Central Asian, sub-Saharan African, South Asian, and Latin American regions, respectively. More than 83% of survivors with kernicterus had one or more impairments.

conclusionFailure to prevent Rh sensitization and manage neonatal hyperbilirubinemia results in 114,100 avoidable neonatal deaths and many children grow up with disabilities. Proven solutions remain underused, especially in low-income countries.

Indexed as

Erythroblastosis, FetalGlobal HealthHistory, 21st CenturyHumansHyperbilirubinemia, NeonatalIncidenceInfant, NewbornModels, StatisticalRh Isoimmunization

Identifiers

PMID24366465
PMCPMC3873706
OpenAlexW2170501460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.